Additional file 1 of Identification of diagnostic model in heart failure with myocardial fibrosis and conduction block by integrated gene co-expression network analysis

Supplementary Material

CNs of genes in the family, other patients and normal controls.

<p>Left: Genes we detected. Right: CNs of the family, two patients, and other samples(50 controls and 48 patients); n: normal ratio comparing with the DNA pool. \: no data.</p

Primers for sequencing TBX-1, TBX-5, GATA-4, GATA-6, SOX7, Nkx2.5 and Fog2.

<p>Primers for sequencing TBX-1, TBX-5, GATA-4, GATA-6, SOX7, Nkx2.5 and Fog2.</p

Comparison among the subjects’ genotypes and symptoms among samples.

<p>+: duplication, −: deletion, n: normal. Losing or gain in the whole segments leads to diseases. REPD variations may not leads to diseases but impacts SOX7 which is related to CHD.</p

The echocardiography images of this case.

<p>MPA: main pulmonary artery, RV: right ventricular, VSD: ventricular septal defect, IVS: inter ventricular septum, LV: left ventricular, AO: aortic artery.</p

Primers of the genes in qPCR.

<p>Primers of the genes in qPCR.</p

The model structure illustrating the five first-line strategies for treating mRCC.

<p>The model structure illustrating the five first-line strategies for treating mRCC.</p

The cost-effectiveness acceptability curves for the five first-line strategies.

<p>(A) without the SPAP; (B) with the SPAP. The y-axis indicates the probability that a strategy is cost-effective across the willingness to pay per QALY gained (x-axis). The bold vertical dashed line represent the thresholds for China.</p

Base-Case Cost Estimates ($, year 2011 values) and Utilities.

*<p>The ranges of costs and utilities were obtained from local charge and literatures, respectively.</p

HR and probabilities of SAEs.

*<p>Probabilities are presented as percentages.</p>#<p>The range is from 90% to 110% of the mean.</p>$<p>We assumed that the probabilities were similar to those in the AVOREN Trial.</p>&<p>We assumed the that probabilities were similar to those in the Gore, M. E. 2010 trial.</p>§<p>Rare data were reported; we assumed that the probability of proteinuria was zero.</p